GC Biopharma secures Indian and Taiwanese approvals for Hunterase, opening a new Asian market for its Hunter syndrome enzyme replacement therapy
Executive summary: GC Biopharma’s Hunterase IV received marketing approval in India, while both Hunterase IV and Hunterase ICV were approved in Taiwan on August 24, 2026. The approvals provide the company with its first commercial foothold in the fast‑growing Asian rare‑disease market, potentially unlocking significant sales and reinforcing its pipeline value.
Who is involved: GC Biopharma (South Korea), Indian Drug Controller General (DCGI), Taiwan Food and Drug Administration (TFDA), and patients with Hunter syndrome (MPS II).
Likely next: GC Biopharma will launch commercial distribution in India and Taiwan, begin post‑marketing safety monitoring, and consider pursuing approvals in other Southeast Asian nations.
The drug approvals granted by India’s Drug Controller General and Taiwan’s Food and Drug Administration allow GC Biopharma to market both the intravenous and intrathecal forms of Hunterase in two key Asian economies. This expands the company’s commercial footprint beyond its existing South Korean and Western markets and addresses a high‑need rare disease patient population. The approvals are expected to generate early‑stage revenue and set the stage for further regulatory submissions in neighboring countries.
Timeline
- — GC Biopharma's Hunter Syndrome Treatment 'Hunterase' Receives Drug Approval in India and Taiwan (PR Newswire)
Analysis — what this means
Likely next events
- Commercial launch of Hunterase IV in India expected Q4 2026
- Taiwan market rollout of Hunterase IV and ICV planned for Q1 2027
- Potential submission for approval in Thailand and Vietnam by mid‑2027
- Post‑marketing pharmacokinetic study results anticipated Q2 2027
Sectors affected
- Rare disease enzyme replacement therapy
- Hunter syndrome (MPS II) treatment
- Pharmaceutical biotech
Regulatory implications
- DCGI approval permits manufacturing, import, and sales of Hunterase IV in India
- TFDA approval authorizes both intravenous and intrathecal formulations in Taiwan
- Both agencies will require routine pharmacovigilance reporting and adverse event monitoring